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1. Introduction 
Since 1992, the application of subthalamic nucleus deep brain stimulation (STN-DBS) for 
Parkinson’s disease (PD) has been shown to induce dramatic and stable long-term 
improvement of patients’ motor symptoms. However, some of the motor symptoms, and 
most of the non-motor symptoms, may not be improved by STN-DBS; in fact, they may 
deteriorate after surgery. Even after the successful introduction of STN-DBS as a treatment 
for PD, controversy still exists over a variety of issues: patient selection criteria, the 
anatomical target such as STN or globus pallidus (GPi), targeting methods (MRI alone, CT 
scan with image fusion, or ventriculography), microelectrode recordings (yes/no), and 
anesthetic procedures  (awake with sedative or under general anesthesia). In this chapter we 
will discuss these controversial issues by integrating our experience with a review of the 
literature. 
2. Patient selection for deep brain stimulation (DBS) 
A successful DBS surgery may involve several surgical procedures, but patient selection is 
always a key issue to address because it contributes to whether there is a good surgical 
outcome. In 1992, a common evaluation protocol for PD was suggested by the the Core 
Assessment Program for Intracerebral Transplantations(CAPIT) committee, which allowed 
for comparisons between different study groups. For example, they defined “off-
medication” and “on-medication” status. The core assessment methodologies of this 
protocol include the following: Unified Parkinson’s Disease Rating Scale (UPDRS), Hoehn 
and Yahr Staging, Dyskinesia Rating Scale, Self-reporting diary, and timed test for 
bradykinesia [1]. In 1996, the Network for European CNS Transplantation and Restoration 
(NECTAR), developed a new  Core Assessment Program for Surgical Interventional 
Therapies in PD (CAPSIT-PD) and  gave advice to add evaluations for cognitive function 
and quality of life [2]. Since then, thousands of papers have been published in the fields of 
PD and DBS, and clinicians and researchers have paid attention to the issue of patient 
selection in order to ensure a good outcome [3-9].  
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In 2009, Australia offered a referral guideline for neurologists to establish methods for 
enrolling ideal PD candidates for DBS. In 2010, consensus was reached for DBS in PD. 
With respect to patient selection, these experts stated that, “...Best results have been 
reported in patients with advanced PD and (1) levodopa response, (2) younger age, (3) no 
or few axial non–LD-responsive motor symptoms, (4) no or very mild cognitive 
impairment, and (5) absence of or well controlled psychiatric disease” [10]. The ideal 
candidate has all of the above components; however, even with these guidelines, pitfalls 
and controversy still exist. 
Diagnosis 
It is important to differentiate PD from atypical parkinsonism to ensure a good long-term 
outcome of STN-DBS, but it can be hard to discriminate between them because they share 
clinical features such as bradykinesia, rigidity and tremor. It is especially difficult when 
the disease is in its early stage and l-dopa responsiveness is moderate. Poor prognostic 
factors for STN-DBS can be the following: a poor response to l-dopa, the additional 
presence of pyramidal or cerebellar signs (e.g., ataxia), an early presentation of posture 
instability and autonomic failure (e.g., hypotension),  within 5 years of onset, a non-
tremor dominant presentation, and persistent unilateral disease [11-12]. The UK Brain 
Bank Diagnostic Criteria for PD is recommended for assessing all surgical candidates, 
although it should be noted that the early symptoms of PD, such as hyposmia, REM sleep 
behavioral disorders,  constipation and depression may precede the obvious motor 
symptoms and are not included on the list [13]. The use of Hoehn and Yahr (H&Y) staging 
and the Unified Parkinson’s Disease Rating Scale (UPDRS) is a basic requirement for 
evaluating patients before starting any PD intervention. In 2007, the revising process for 
the UPDRS was started by a task force of the Movement Disorder Society (MDS), which is 
aimed at incorporating more detail on non-motor symptoms, but it has not yet been 
published [14-17]. 
Age at time of surgery 
Age is a confounding factor and has a negative correlation with STN-DBS outcome. A trend 
for greater long-term STN-DBS improvements on the UPDRS  part II and part III measures 
in younger patients has been shown; however, it is also effective in elderly patients, though 
the benefits may persist for only a short period of time [18]. Most studies also have shown a 
negative correlation with motor outcome, non-motor outcome (e.g., apathy and depression) 
and quality of life upon long-term follow-up [18-22]. While the cut-off age proposed by most 
studies is 70 years old, the benefits and risks of surgery should be weighed to meet the 
expectations of the patient and the care giver. 
Disease duration and severity 
Advanced PD patients with obvious  medication side effects of motor fluctuation and/or 
dyskinesia would be good candidates for DBS. However, an H&Y Stage 1 patient with 
tremor dominant symptoms who is within 5 years of onset can also be a good candidate for 
DBS and show a substantial benefit, as can a bed-ridden Stage 5 patient. Because there have 
been no proven neuroprotective effects of DBS, the recommendation for an earlier 
intervention is based on  quality of life, which will improve substantially in domains related 
to movement disorders and general health [23]. Though some authors postulate that disease 
severity may be correlated with STN-DBS outcome, a study of ours found that the outcome 
was not correlated with H&Y staging or disease duration [18]. 
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Levodopa (LD) responsiveness 
LD responsiveness, as measured by the UPDRS part III, may predict the motor outcome of 
STN-DBS in a PD patient with disabling motor fluctuations and dyskinesia. In fact, this is 
true for all cardinal symptoms (except LD refractory tremor) that can be well controlled by 
STN-DBS. Pre-operative LD responsiveness may only lead to consistent UPDRS part III 
improvement from STN-DBS at 3 months, and its predictive value may not be valid for 
long-term follow-up due to co-morbid non-motor symptoms. The pre-operative LD 
responsiveness of tremor and axial symptoms are stable predictors for the long-term effect 
of DBS [18]. 
Cognitive, psychiatric, and other non-motor symptoms 
Non-motor symptoms in PD patients are a significant source of disability and impairment in 
the performance of activities of daily living. The non-motor symptoms of PD include 
dementia, sleep disorders, and dysautonomia along with neuropsychiatric and sensory 
complaints. Most centers exclude PD patients with dementia and neuropsychiatric 
symptoms from STN-DBS. As for sleep disorders and sensory complaints, some reports 
have shown improvement after treatment when these symptoms are present. More 
generally, normal pre-operative cognitive functioning is positively correlated with post-
operative improvement in UPDRS part III at a long-term follow-up [18]. STN-DBS may still 
lead to a decline in cognitive and executive function even with strict inclusion criteria [24]; 
however, it has been suggested that sub-optimal contact stimulation (caused by the small 
volume of STN) is more strongly correlated with post-operative psychiatric events. 
Although there are still debates about post-operative psychiatric events, the possibility of 
increased depression and suicide risk prompts us to evaluate the patient’s psychological 
function in detail prior to the operation. 
3. STN-DBS versus GPi-DBS: Which target is better for PD patients? 
STN-DBS is the current gold-standard surgical treatment in PD, but a high occurrence of 
adverse effects and neuropsychological problems following STN-DBS stimulation cause 
some centers to study alternative surgical targets, such as the GPi. The issues to consider 
when choosing a target for DBS include the following: a different set of patient selection 
criteria, the amount of levodopa being used, the extent of levodopa-related dyskinesia, 
battery life and surgeon preference. 
In randomized trials, DBS has been demonstrated to be superior to the best known-
medical treatment for advanced PD. Under most circumstances, STN is the chosen target 
rather than GPi. Although several reports have shown that the efficacy of pallidal 
stimulation decreases over the long-term follow up [25], others have demonstrated a 
persistent benefit from pallidal stimulation for up to 3 years [26]. In 2005, the first 
randomized trial was published by Anderson and colleagues, and their patients showed a 
similar improvement in motor function from subthalamic and pallidal stimulation [27]. 
Still, deciding which target is best is a topic still subject to debate, and several points of 
view need to be considered. 
The effect of target on motor function 
PD is characterized by disabling motor symptoms. Previous reports seem to have concluded 
that STN-DBS improves more than GPi-DBS in UPDRS part III (motor) [26-28]. However, a 
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recent large randomized trial showed a similar improvement from either STN or GPi 
stimulation [29]. It should be noted that the follow-up duration in this study was only 24 
months and GPi might show less of a benefit after a longer period of time [25, 30]. 
The effect of target on non-motor symptoms 
Non-motor symptoms of PD have received more attention in recent years and seem to play 
a pivotal role in the change in quality of life caused by the amelioration of motor disabilities 
through medical or surgical treatment [31]. An increased percentage of post-stimulation 
behavioral and cognitive complications is still a major concern for STN-DBS [27, 32-33] as it 
is not conclusively known whether DBS causes a change in these non-motor symptoms. 
Although a recent randomized trial comparing PD patients undergoing STN stimulation to 
those who only received the best medication-based treatment showed no significant 
differences [34], a second study comparing STN stimulation with GPi did show that 
depression was worse in those who received STN-DBS [29]. This finding reminds us that 
non-motor symptoms should be considered during target selection for patients who plan to 
receive electrode implantation. 
The effect of target on reducing medication dosages 
One of the main reasons that pallidal stimulation has not become popular may be that it 
limits the amount one can decrease medication dosages. Most studies have shown that 
patients who undergo STN stimulation require a lower dose of dopaminergic medication 
than those who undergo GPi stimulation [28-29]. This effect is probably due to different 
mechanisms of action underlying the STN and GPi response to electrical current. It has been 
suggested that STN stimulation reverses the sensitization phenomenon that underpins 
levodopa induced dyskinesia (LID) [35]. In fact, STN stimulation per se cannot ameliorate 
LID without decreasing dopaminergic medication[36]. Contrary to this, GPi stimulation 
may itself decrease the severity of LID [37]. The interaction between STN and GPi activity 
has been suggested to play a major role in the pathogenesis of dyskinesia, and the 
amelioration of stimulation-related dyskinesia through proximal contact (i.e., stimulating 
pallido-subthalamic fibers) shown in previous reports and our own young onset PD (YOPD) 
patients suggests a more beneficial effect of GPi than STN in ameliorating treatment-related 
dyskinesia. Overall, most comparative studies showed that the daily dosage of levodopa can 
be reduced only in an STN-DBS group [26]. 
The effect of target on battery life 
The stimulation amplitude within the implantable pulse generator (IPG) is one significant 
determinant of battery life. In a multicenter study,  Rodriguez-Oroz and colleagues found a 
similar amplitude for patients undergoing STN and GPi stimulation for 3 to 4 years [26]. 
However, most studies (including one large randomized trial) have shown that STN 
stimulation requires significantly less electrical power  around 0.7~0.8 V and a pulse width 
of 20 μsec [38]. These parameters allow patients to receive STN stimulation for a longer 
period of time between pulse-generator replacements as compared to GPi stimulation. Most 
cost-effectiveness studies also have confirmed this benefit of STN stimulation over solely 
medication-based treatment for advanced PD. For countries where DBS devices are not 
reimbursed by health insurance, such as Taiwan, the replacement of the IPG will be a large 
burden for most patients. Larger amplitudes and pulse widths for GPi stimulation may lead 
to more frequent battery replacement and more device-related complications [30]. 
Improving future IPG technology may alleviate this economic consideration. 
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Adverse effects of target 
Adverse effects of stimulation in general include cognitive decline, verbal fluency 
deterioration, gait disorders and mood instability (in the form of compulsiveness or 
depression). Most studies show that the adverse effects of stimulation are more common in 
STN-DBS [27, 29]. In the  COMPARE trial, which was a prospective randomized trial, it was 
shown that under optimal conditions there was no significant difference in the incidence of 
mood or cognitive alteration following DBS implantation. However, a sub-scale analysis of 
the Visual Analogue Mood Scale showed that there was more “anger” after STN-DBS. 
Another randomized trial also has suggested that depression may be worse after 
subthalamic stimulation but improved after pallidal stimulation.  
The volume of the STN (~158 mm3) is much smaller than the GPi (~478 mm3) nucleus. 
Moreover, the sub-territory within the STN nucleus and surrounding fibers involve motor, 
associative and limbic circuitry that are more compact and close together. Therefore, a sub-
optimal electrode placement or electrical-current perturbation is more often going to be 
associated with STN stimulation, which may lead to mood changes and verbal fluency 
dysfunction. 
Although  a randomized control trial has shown a comparable benefit for GPi stimulation 
compared to STN stimulation, longer follow-up studies are needed to decide which target is 
preferable for each patient. We have made a comparison of the targets in Table 1. Clinical trials 
are ongoing for alternative targets in the pedunculopontine nucleus, radiation prelemniscalis, 
and caudal zona incerta, and stimulation on these targets may improve symptoms that are 
currently unresponsive to treatment with either levodopa or STN stimulation. 
 
 STN stimulation GPi stimulation 
Motor improvement 50~60%, coherent [29, 34] 27~50%, variable in long-term [29, 72] 
Mood effect higher, esp. suboptimal 
contact 
seems unchanged 
LEDD reduction greater reduction (31.5%) less reduction (17.8%) 
Battery life lower amplitude higher amplitude 
General adverse effect 56% 51% 
Table 1. Comparison of STN and GPi stimulation 
4. Targeting methods in DBS: MRI alone versus CT scan fused with MRI 
and/or ventriculography 
There are a number of targeting methods used in DBS. Which method is used depends on 
the facilities of the institution and the familiarity of the surgeon with a given procedure. 
Most practicing centers use magnetic resonance imaging (MRI) as the only tool for targeting, 
but others use image fusion techniques to co-register MRI and computed tomography (CT) 
images, or intra-operative ventriculography, which is the traditional targeting method, for 
determining targeting accuracy. Below we compare these methods on acquisition time, 
procedure complexity, and ultimate accuracy. 
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The size of the STN is extremely small and it has an ovoid shape and oblique orientation 
[39]. The accuracy of DBS targeting may be one of the most important factor in surgical 
outcome because the position of the electrode determines the area across which the electrical 
current diffuses. Given that there are very few evidence-based studies that have directly 
compared the safety and effectiveness of the various imaging techniques, the best targeting 
method remains under debate. The methods include MRI, CT, ventriculography and various 
combinations thereof. 
Stereotactic targeting with ventriculography is the traditional method for stereotactic 
functional neurosurgery that has been in use for decades. While it is still used by some 
teams, there are concerns over its invasiveness and serious complications, such as CSF 
leakage and intracranial hemorrhage, which are major obstacles for most functional 
neurosurgeons [40].  The method involves injecting a contrast medium into the right frontal 
horn and acquiring representative images to determine the location of the anterior 
commissure and posterior commissure, which then can be used to calculate various target 
coordinates [41]. Compared with targeting methods that may have higher accuracy (e.g., 
ventriculography), targeting with MRI can be affected by the anterior displacement of the 
anterior commissure (AC), which elongates anterior commissure - posterior commissure 
(AC-PC) length [40]. A magnetic field can cause this nonlinear distortion, especially in the 
anterior-posterior and medial-lateral axis. 
Most centers only use MRI for targeting while others use image fusion techniques to co-
register MRI and CT scans. MRI-directed targeting for STN-DBS has proven to be a simple 
yet accurate method in most DBS practicing centers; it has been a standard procedure in our 
hospital since 2002 [42]. The advantages of MRI includes better demarcation of deep nuclei 
(e.g., the red and subthalamic nucleus) as references for targeting, better visualization of 
critical structures that can prevent inadvertent injury (e.g., lateral ventricles and 
vasculatures within sulci) and a clear delineation of simulating trajectory for electrode. 
There are three current strategies to localize the coordinates of targets on stereotactic MRI. 
In direct targeting, the STN is located on MRI without any references, which is inherently 
prone to errors. The vague configuration of the STN makes determining the STN boundaries 
on a T2-weighted MR image rely on the subjective visual impression of the neurosurgeon. 
An indirect method of targeting uses the AC and PC as reference points, thereby avoiding 
bias when differentiating the border between the STN and substantia nigra, which has been 
shown to be more accurate than direct targeting. Targeting based on the red nucleus (RN) 
has not only the same accuracy as indirect targeting but also less variance, which indicates 
greater precision across subjects (Fig. 1) [43]. Although MRI-based targeting is becoming 
more popular, the potential distortion of the STN that a nonlinear magnetic field can induce 
is still a major concern. To counter this, some groups still use ventriculography which 
reliably identifies the AC-PC for indirect targeting methods using intraventricular 
landmarks. 
Although the AC-PC and the target itself (e.g., the STN) are poorly visualized on CT, MRI 
fused to stereotactic CT are believed to combine the advantages of both modalities, thereby 
increasing the spatial validity of the image and ensuring a more accurate localization, which 
continues to improve as fusion technology improves [44]. In our experience, stereotactic CT 
fused to MRI during DBS surgery can allow for a longer microelectrode recording length of 
STN and fewer recording tracts (Fig. 2). This indirectly demonstrates that stereotactic CT 
may have a better pre-operative targeting ability leading to the stimulation of optimal 
anatomical sites. It should be noted that it may be difficult for advanced PD patients to 
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Fig. 1. Direct targeting using MR images is depicted. The target coordinates for the tip of the 
permanent implantable electrode are at the intersection of the perpendicular lines. The 
horizontal line is located along the anterior border of the red nucleus. The longitudinal lines 
are at 2-mm intervals from the lateral border of the red nucleus. Axial section taken at the 
level of the superior colliculus, just below the lowest border of the STN (4.5 mm below the 
mid–commissural point). 1= red nucleus; 2=substantia nigra reticulata; 3=crus cerebri. 
undergo MRI with a stereotactic frame, especially in an un-medicated state where obvious 
tremors or severe stoop posture will be present. There is a risk for these patients when 
sedated in the MRI suite in an attempt to quell the severe tremor because the scanning time 
for MRI may take more than 20 minutes. For this reason, some centers use a specific protocol 
for direct visualization of the STN in stereotactic MRI, which saves time [45]. At our 
institution, a stereotactic CT scan takes about 3 minutes, which is far below the average MRI 
acquisition time of 20-25 minutes for most protocols. 
With advances in imaging technology, we may be able to define the border of the STN 















Fig. 2. (A) Stereotactic axial computed tomography (CT) images for fiducial registration. (B) 
Nonfused axial magnetic resonance image (MRI) T1 images and stereotactic CT images. (C) 
Co-registered Schaltenbran-Wahren atlas for red nucleus and subthalamic nucleus (STN) 
target planning simulation. (D) Fused axial MRI T2 and CT images, spyglass with 
visualization of red nucleus (thin arrow) and STN (thick arrow). 
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5. The necessity of microelectrode recording in STN-DBS surgery 
Precise results in DBS surgery are traditionally achieved by MRI targeting followed by 
electrophysiological confirmation with microelectrode recording (MER) [46]. MRI scans are 
not always of sufficient quality to identify the target structure and are always susceptible to 
image distortion. MER can localize the target with more precision when MRI targeting is not 
precise enough. MER is used in DBS surgery to identify the target’s structural border, the 
subdivisions of the targeted structure and the outlines of its three-dimensional shape. MRI 
and MER are complementary in DBS surgery [47]; however, there are disadvantages of MER 
in DBS surgery, including the following: 1) it is time consuming, 2) it may increase the risk 
of a hemorrhage complication and 3) it is not always useful, for example when the target is 
located in white matter or has a large and distinct boundary that can be easily visualized 
with MRI. Here we will focus on whether MER is necessary in STN-DBS surgery for treating 
PD. 
Direct MRI targeting without MER is possible in STN-DBS surgery with the recent advances 
in high-resolution MRI (field strength of 3-Tesla or more) and advanced image processing 
techniques. However, there is a paucity of publications that report on the use of stereotactic 
MRI for direct visualization in STN-DBS surgery without MER [48]. Recently, a large series 
of STN-DBS without MER has been published by Foltynie et al. [49]. We compared their 
results with those of Krack et al [50], who performed STN-DBS with MER which recruited 
from a single center. Table 2 compares the demographic data of the studies’ patients, effect 
of DBS and complications of surgery. The baseline data of the patients are comparable 
except that Krack’s sample size is less than Foltynie’s. However, we should note that Krack’s 
report is designed for long term follow-up (5 years later) and they recruited the first 49 STN-
DBS patients from their center. The effect of STN-DBS at a one-year follow-up was similar in 
the two studies. The DBS effect is better in Krack’s study but not significantly so. In terms of 
surgery-related adverse events, Krack showed greater transient confusion and intracerebral 
hemorrhage in their patients. Foltynie showed less transient confusion and no hemorrhage 
events. 
The risk of intracerebral hemorrhage inevitably increases with a greater number of micro- or 
DBS electrode penetration events [51-52]. Post-operative transient confusion in DBS surgery 
is common. The incidence of transient confusion in STN-DBS surgery is 15.6% [53]. This 
phenomenon is often attributed to a mild pneumocephalus that occurs during surgery. It is 
not a precisely understood phenomenon, but it occurs more frequently in older and 
cognitively disabled patients. The risk for and volume of pneumocephalus positively 
correlates with the amount of time the skull is open during surgery. MER may therefore 
increase the risk of pneumocephalus because it is time consuming. 
Based on the above comparison, the same therapeutic effect for patients can be achieved in 
STN-DBS with and without MER, but MER has more surgery-related adverse events. Others 
have reported that the use of MER improves the outcome of STN-DBS [42]. With the 
advancement of MRI technology and imaging processing, MRI-guided STN-DBS without 
MER may be an alternative surgical method for advanced PD patients. The reports of MRI-
guided STN-DBS are sparse; therefore, we cannot conclude that this surgical method is 









(Krack et al) 
Without MER 
(Foltynie et al) 
Demographic data Mean ± SD Mean ± SD 
Sex (no. of patients) 24 men / 25 women 49 men / 30 women 
Age at surgery 55.0 ± 7.5 (34-68) 57.3 ± 7.7 (34.5-70.2) 
Duration of disease 14.6 ± 5.0 13.4 ± 7.0 
L-dopa equivalent dose 1409.0 ± 605.0 1620.0 ± 641.0 
Effect of STN DBS       
UPDRS III motor scores 
Baseline off-medication 
55.7 ± 11.9 51.5 ± 14.9 
UPDRS III motor scores 
One year after operation 
on-stimulation, off-medication 
19.0 ± 11.1 23.8 ± 11.2 
UPDRS III motor scores 
One year after operation 
on-stimulation, on-medication 
11.4 ± 8.9 14.5 ± 8.3 
Adverse events related to procedure       
Intracerebral hemorrhage 2   0   
Transient confusion 12   7   
Seizures 2   2   
 
 
Table 2. Comparison between DBS with and without MER 
6. Anesthetic considerations in DBS: Awake versus general anesthesia 
Traditionally, DBS is an awake surgical procedure in order to allow electrophysiological 
mapping and stimulation testing to assess motor responses and potential side effects. 
However, PD patients with obvious “off-medication” symptoms of anxiety, painful 
dystonia, and respiratory distress may not be good candidates for the lengthy tolerating the 
surgical procedures while awake [54-57]. In this section, we will report our own experience 
with general anesthesia during DBS surgery with MER and compare it with data from 
awake procedures (see Table 3). 
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Operation procedures: Awake DBS General Anesthetic DBS 
Patient’s condition communicative and 
cooperative; Can tolerate 
severe off-symptoms 
Anxious; Cannot tolerate 
severe off-symptoms, 
such as: pain, dystonia 
and/or respiratory 
difficulties 
Anesthetic agents None Desflurane (Patient 
intubated under regular 
induction and muscle 
relaxant, keep Mac 
around 0.8~1.0) [54] 
Sedative agents propofol / remifentanil 
(intermittent use, e.g. 
during trephination) 
None 
MER signals Yes Yes 
Passive movement-related MER 
signals 
Yes Yes 
Test stimulation Yes No 
Motor outcome Good Good 
Surgical complication Comparable Comparable 
Stimulation side effect Lower May be higher 
Risk period During surgery Induction and extubation 
Patient monitoring by anesthesiologistYes Yes 
Mac: minimum alveolar concentration 
Table 3. Comparison between awake DBS and general anesthetic DBS procedures 
Awake DBS procedures 
Most DBS centers prefer that their PD patients receive electrode implantation procedures in 
an awake state in order to retrieve sound electrophysiological signals from MER and to 
perform test stimulation. Time is crucial for a patient to tolerate the procedure while awake.  
Patel et al tried an MRI direct-targeting method with macro-stimulation alone. They 
conclude that without MER the procedure is more efficient and safe but still has a good 
outcome [58-59].  In the awake state, macro-stimulation is beneficial because it excludes the 
side effect from electrode stimulation [59]. Sedative agents are inevitable during awake 
procedures, especially during trephination. Propofol is popular during DBS procedures as a 
brief general anesthetic agent, but it may require full-time surveillance of the patient’s 
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airway and vital signs by an anesthesiologist.  The function of the patient’s airway can be a 
severe problem in an advanced PD patient’s “off” state. 
MER has been shown to perform properly and without affecting the surgical outcome only 
when remifentanil was completely stopped and the dose of propofol was carefully 
monitored [52, 58, 60-61].  Duque et al reported a case with these same anesthetic agents 
using Bispectral Analysis of the Electroencephalogram (BIS) to monitor cortical activity in 
order to titrate the hypnotics, which may interfere with MER procedures. While this 
technique may be useful, it is not convenient [62]. 
General anesthetic DBS procedures 
A detailed MER mapping within the STN may lead to an optimal placement of DBS 
electrodes, but the drawbacks are the length of the procedure and that the patient must be 
kept awake during the procedure. Some patients with severe “off-medication” PD 
symptoms, such as major anxiety, poorly tolerated off-medication dystonia, or respiratory 
difficulties may refuse DBS or may be poor candidates for DBS in an awake state [55, 57]. 
STN-DBS during a state of general anesthesia may be another choice for those patients with 
advanced PD for whom symptoms are difficult to control with medication only. 
In patients with advanced PD who undergo STN-DBS while awake, test stimulation after 
the permanent electrode is implanted is helpful to confirm the electrode position. The test 
stimulation verifies the maximal clinical effects intraoperatively as well as the side effects 
of low voltage in the case that the electrode position was sub-optimal. Test stimulation in 
patients receiving a general anesthetic is controversial. Hertel et al. performed test 
stimulation to verify possible capsular effects when using low-voltage electrode 
stimulation, and the voltage causing the capsular effects may be incorrectly estimated if 
the excitability of the capsule has been decreased by general anesthesia. In our study, we 
did not perform test stimulation, but no patient suffered post-operative capsular effects 
because our selection criteria for the trajectory of electrode implantation chose the most 
appropriate track [54]. 
The knowledge of STN topography is crucial in general anesthesia DBS surgery; therefore, 
MER must be used as it is the only intra-operative tool to identify the STN, map its 
boundaries, and map its sensorimotor component through the detection of movement-
related neuronal firing [61, 63-65]. 
The role of anesthesiologist in DBS surgery 
Most anesthesiologists are treating intubated patients under general anesthesia and in 
awake procedures like DBS, it can be challenging to ensure neuronal firing on the one hand 
and monitor patient safety the other. Avoiding medications that may interfere with MER 
can negatively affect patient safety, especially when the patient is agitated by a prolonged 
DBS procedure. However, it also is difficult to maintain a secure airway if the patient is too 
deeply unconscious [66-67]. In hypertensive patients, the alpha-2 agonist dexmedetomidine 
has been suggested as an effective sedative agent that may provide the patient comfort and 
good blood-pressure control and yet still allow satisfactory MER mapping by the 
neurophysiologist [67]. Complications may still occur during awake DBS procedures. 
Deoganokar reported a case of venous air embolism in an elderly PD patient with a 
myocardial infarction [68]. Glossop and Dobbs also report two cases of coronary artery 
vasospasm during electrode implantation. Though these patients recovered, the authors 
suggest full monitoring by an anesthesiologist throughout the surgical procedures [69]. 
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The effect of the anesthetic agent desflurane 
Desflurane (2,2,2-trifluoro-1-fluoroethyl-difluoromethyl ether) is a highly fluorinated 
methylethyl ether used for maintenance of a general anesthetic. It has the most rapid onset 
and offset of all of the volatile anesthetic drugs used for general anesthesia because of its 
low solubility in blood. It also is popular in neurosurgery because it can allow early 
extubation and facilitate early neurological evaluation [70-71]. MER also can be performed 
well at an anesthetic level of 0.8±0.2 minimum alveolar concentration (MAC) [54]. 
7. Conclusion 
The subthalamic nucleus plays an important role in the functional control of motor activity 
in the indirect dopaminergic pathway of the basal ganglia. Twenty years after the first 
introduction of DBS to treat PD, it remains as an important alternative treatment to l-dopa, 
especially in the patient with motor fluctuation and obvious l-dopa related complication. 
Centers performing DBS may have different protocol according to their experiences and 
facilities. Controversial points exist inevitably, however, through proper patient selections, 
cooperation between multidisciplinary teams, and refine surgical techniques we can ensure 
a good outcome for DBS candidate. 
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